Long-Term Lamotrigine Adjunctive to Antipsychotic Monotherapy in Schizophrenia: Further Evidence
Dear Editor:
Adding anticonvulsants to antipsychotics has been reported to improve symptoms in schizophrenia (1) . Dursun and others added lamotrigine to clozapine for treatment-resistant patients and obtained positive results over 24 weeks (2, 3) . Saba and others obtained similar results over 12 weeks (4) . We further studied the effect of long-term adjunctive lamotrigine on standard antipsychotic monotherapy (specifically, haloperidol, risperidone, or clozapine) in patients with schizophrenia.
Subjects included 10 outpatients with a DSM-IV diagnosis of schizophrenia (8 men and 2 women aged 22 to 49 years; mean age, 30.7 years) enrolled in the following studies: RIS-INT-35 (n = 7), a double-blind study of risperidone vs haloperidol in new-onset schizophrenia; RIS-INT-57 and RIS-INT-63, (RIS-CONSTA studies, n = 1 each); and InterSePT study (n = 1) of clozapine vs olanzapine in suicidal patients with schizophrenia (5) . Lamotrigine was used as open-label adjunctive therapy. The mean daily dosage of lamotrigine was 232.5 mg (range 25 to 400 mg/daily) over a mean period of 132 weeks (range 30 to 220 weeks).
Patients were treated for up to 220 weeks with no relapses. The medication was well tolerated, with no major adverse events. We measured changes in Positive and Negative Symptoms Scale (PANSS) scores and Clinical Global Impression (CGI) scores from initiation of lamotrigine to most recent observation. No patient worsened significantly. Six out of 10 patients showed an average improvement of 1.5 points on the CGI. The mean (SD) change in CGI for the entire group was 4.1 (0.9) to 3.2 (0.8). Two of 10 patients had a marked decrease in their total PANSS scores (-39 and -49 points). The mean (SD) change in total PANSS score for the entire group was 77.3 (35.1) to 64 (25.5).
A model of psychosis based on N-methyl-D-aspartate (NMDA) antagonists (specifically, phencyclidine or ketamine) proposes that NMDAreceptor hypofunction contributes to the pathophysiology of schizophrenia (6). Anand and others reported that lamotrigine attenuates the neuropsychiatric effects of ketamine in healthy volunteers (7) . Olney and others propose that lamotrigine may compensate for the functional hypo-NMDA state by suppressing excessive glutamate release and the spread of abnormal neural activity occurring in schizophrenia (8) . Abnormal glutamatergic neurotransmission in the prefrontal cortex may represent a mechanism by which stress exacerbates symptoms in this vulnerable population (9) .
Our data are consistent with the report of Dursun and others (2) . We conclude that the addition of lamotrigine to low-dose risperidone, haloperidol, or clozapine produces overall benefit in patients with schizophrenia, including first-episode patients. Controlled clinical trials are warranted to evaluate efficacy and to clarify which patients benefit most from adjunctive lamotrigine. health workers. They focus on engaging the client, they consider medication (usually low-dosage atypical antipsychotics), and they attempt to restore vocational or educational functioning as symptoms improve. Families or other caregivers are closely involved in monitoring the patient's mental state and are given education and support. Studies in this area encounter methodological difficulties, particularly in sample size, purity, and retrospective designs; however, emerging evidence supports this work.
Clinicians can now identify young people exhibiting prodromal symptoms of impending psychosis with increasing accuracy (1). However, clinical and ethical concerns exist with treatment at this stage (particularly with medication). Moreover, family reactions may possibly be unhelpful, and stigma accompanies the use of psychiatric services. Using psychosocial strategies targeted to the presenting complaint and monitoring without medication, except when positive symptoms develop, should allay many concerns (2) . The attractiveness of this work from clinical, epidemiologic, and resource perspectives encourages further investigation.
Where positive symptoms develop, the duration of untreated psychosis (DUP) is emerging as a predictor of future disability and illness course, particularly when it exceeds 1 year. Specifically, Loebel found that, rather than premorbid adjustment, age of onset, mode of onset, or illness severity, DUP best predicted the time to treatment response (3). The Northwick Park Study showed that DUP of less than 1 year was a stronger predictor of avoiding relapse at 2 years than was maintenance-medication status (4). Loebel postulated that active psychosis may represent the expression of a toxic neurobiological process, with each subsequent relapse rendering the patient more susceptible to another (5) . For these reasons, early detection and prevention, or early treatment of relapse, are crucial foci of services. The etiology of delayed initial treatment is complex; it includes factors related to the mode and rapidity of illness onset, patient factors related to help seeking and the social support network, and systems issues relevant to the ease of service access (6) . Therefore, any attempts to reduce the DUP must come from a multilayered approach; a broad educational focus is needed to reduce treatment delay and to ensure prompt, effective treatment from EI teams once psychosis is detected.
Eaton and others showed that many measures of symptomatology and psychosocial outcome taken 2 years after treatment of the initial psychotic episode are little different from those taken many years later (7) . This suggests that after a "critical period" (8) early in the illness course, the sustained level of general disability does not change. This implication is double-edged: it provides further evidence against the progressive deterioration described by Kraepelin, but it also suggests that for many patients the expectations of functional or symptomatic recovery are limited after a certain period of being unwell. We propose that assertive attempts to reduce symptoms and restore social and vocational status during this period may have disproportionately beneficial long-term effects, although clear evidence for this does not yet exist.
Current research increasingly supports such clinical targets as preventing movement from the prodromal phase to acute psychosis, reducing the length of unresolved psychosis, and implementing assertive psychosocial interventions in the recovery period. Further longer-term prospective studies with data regarding illness course in treatment, as well as cost, will add to current knowledge.
D 2 Antagonist Augmentation in Patients With a Partial Response to Atypical Antipsychotics
Atypical antipsychotic medications have become the first-line treatment for schizophrenia (1) because of their broader efficacy and lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) (2). Clozapine is indicated in treatment-resistant schizophrenia (3); however, for patients who cannot tolerate clozapine therapy or who reveal only partial response to it (4), targeted treatment strategies tailored to the variable expression of schizophrenia in each patient are in order (5) . Coprescribing typical, atypical, and depot antipsychotic agents may be considered (6) .
We report 4 cases of individuals who met DSM-IV criteria for schizophrenia that only partially responded to monotherapy. For 12 weeks, a classic antipsychotic agent was added to ongoing atypical drug
